

U.S. Application No. 10/800,407  
Filed: March 12, 2004

### LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A pharmaceutically acceptable solid anthelmintic formulation comprising a combination of a first active ingredient comprising particles of an avermectin that had been spray granulated with at least one carrier selected from the group consisting of polyethylene glycol or cellulose; a second active ingredient comprising an anthelmintic pyrimidine ~~a tetrahydropyrimidine~~; a third active ingredient, comprising a hexahydropyrazinoisoquinoline and a fourth active ingredient comprising a benzimidazole or a probenzimidazole.
2. (previously presented) The formulation of claim 1, wherein the first active ingredient comprises ivermectin.
3. (previously presented) The formulation of claim 1, comprising at least about 0.005% ivermectin.
4. (previously presented) The formulation of claim 1, comprising about 0.012 – 5% ivermectin.
5. (previously presented) The formulation of claim 1, comprising a tetrahydropyrimidine ~~an anthelmintic pyrimidine~~.
6. (previously presented) The formulation of claim 1, wherein the second active ingredient comprises a pyrantel.
7. (previously presented) The formulation of claim 6, wherein the pyrantel comprises pyrantel pamoate.
8. (previously presented) The formulation of claim 1, comprising at least about 1.5% pyrantel.
9. (previously presented) The formulation of claim 1, comprising about 11.2 – 33% pyrantel.

SSL-DOCS\1690721\1

U.S. Application No. 10/800,407  
Filed: March 12, 2004

10. (previously presented) The formulation of claim 1, wherein the third active ingredient comprises praziquantel.

11. (previously presented) The formulation of claim 1, comprising at least about 2.0% praziquantel.

12. (previously presented) The formulation of claim 1, comprising about 8.2 – 23% praziquantel.

13. (previously presented) The formulation of claim 1, comprising at least about 25.3% fenbendazole.

14. (previously presented) The formulation of claim 1, comprising about 30.0 – 45.0% fenbendazole.

15. (previously presented) The formulation of claim 1, comprising at least about 15.2% febantel.

16. (previously presented) The formulation of claim 1, comprising about 19.4 – 31.6% febantel.

17. (previously presented) The formulation of claim 2, in a form that will remain stable and pharmaceutically active, in a solid form, for over one month.

18. (previously presented) The formulation of claim 17, wherein there is an effective amount of pharmaceutically acceptable carrier material to prevent the ivermectin from degrading sufficiently to eliminate its pharmaceutical effectiveness.

19. (currently amended) An anthelmintic formulation, which is in the form of a tablet, consisting essentially of comprising an avermectin; a tetrahydropyrimidine; a hexahydropyrazinoisoquinoline; a benzimidazole or a probenzimidazole and a suitable carrier, in a condition that will remain active and in its tablet form for over one month.

SSL-DOCS1 1690721v1

U.S. Application No. 10/800,407  
Filed: March 12, 2004

20. (currently amended) The formulation of claim 19, comprising ivermectin that has been granulated with at least one carrier selected from the group consisting of polyethylene glycol or cellulose material surrounding the ivermectin.

21. (currently amended) A method for forming an anthelmintic formulation comprising the steps of:

(A) preparing a combination of ivermectin and at least one ~~a second material~~ carrier selected from the group consisting of polyethylene glycol and cellulose;

(B) spray granulating the combination to form granules, with the carrier ~~second material~~ covering the ivermectin; and

(C) combining granules with an additional active ingredient composition.

22. (previously presented) The method of claim 21, wherein the additional ingredient composition comprises pyrantel pamoate, praziquantel and fenbendazole or febantel.

23. (previously presented) The method of claim 21, wherein the formulation is pressed into a tablet or enclosed in a capsule and the ivermectin has been effectively isolated, so that the formulation will stay stable for over one month.

24. (previously presented) An anthelmintic formulation, which is formed by the method of claim 21.

25. (previously presented) A method of controlling helminth infestation in animals, comprising administering a pharmaceutically effective amount of the formulation of claim 2 to an animal in need thereof.

26. (previously presented) The method claim 25, wherein the animal is a dog or cat.

27. (previously presented) The method claim 25, wherein the administration comprises administering 5 –7 µg/Kg body weight of the animal dog or cat.

SSL-DOCS1 1690721v1